咳嗽变异性哮喘与嗜酸粒细胞性支气管炎表型与疗程研究进展  

Study of the Phenotype and course of treatment of cough variant asthma and eosinophil bronchitis

作　　者：陈颖 黄俊文 杨淑銮 彭显如 王燕红[1] 赵海金[1] CHEN Ying;HUANG Junwen;YANG Shuluan;PENG Xianru;WANG Yanhong;ZHAO Haijin(Laboratory of Chronic Air-way Diseases,Department of Respiratory and Critical Care Medicine,Nanfang Hospital,Southern Medical Universi-ty,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院呼吸与危重症医学科慢性气道疾病实验室,广州510515

出　　处：《实用医学杂志》2022年第15期1851-1855,共5页The Journal of Practical Medicine

基　　金：国家自然科学基金项目(编号:81770033,81900027,82070030);广州市科技计划项目(编号:201804010069)。

摘　　要：咳嗽变异性哮喘(CVA)和嗜酸粒细胞性支气管炎(EB)是慢性咳嗽常见原因。CVA患者具有气道高反应性,而EB患者以嗜酸粒细胞气道炎症为主要特征,无肺功能异常。吸入性糖皮质激素(ICS)是治疗两种疾病最主要的方法,可以显著改善疾病症状及临床预后。但ICS具体治疗时长与疾病进展的关联尚不甚清楚,各种指南也存在推荐差异,本文重点阐述CVA和EB的不同表型与预后,分析ICS治疗时长对疾病预后的影响因素。Cough variant asthma(CVA)and eosinophilic bronchitis(EB)are the most common causes of chronic cough.CVA patients are mainly characterized by airway hyperresponsiveness,while EB patients are mainly characterized by eosinophilic airway inflammation and normal lung function.The principal treatment of two diseases is inhaling corticosteroids,which can significantly improve the symptoms and prognosis of these two diseases.However,the association between the duration of ICS treatment and disease progression remains unclear,and there are also diversities in various guidelines.This article aimed at elaborating the different phenotypes and prognosis of CVA and EB,and analyzing the influence factors of the duration of ICS treatments on the prognosis of the diseases.

关 键 词：咳嗽变异性哮喘 嗜酸粒细胞性支气管炎 疗程 预后 

分 类 号：R256.12[医药卫生—中医内科学]